Gray-Zone Lymphoma

hematologic malignancy

Identifier: CI-CAN-00005443
Entity page: /cancer/gray-zone-lymphoma ↗
Edges: 38

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Gray-Zone Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 20show all (up to 200)
→ investigated in trials for	Cyclophosphamidesmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Gray-Zone Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule

Gray-Zone Lymphoma studied in …STUDIED_INderived10 of 18show all (up to 200)
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03602157Phase 1 · active not recruiting Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped CURATED_BROADER · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03749018Phase 2 · active not recruiting Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · condition mapped ALIAS · 18 trials mapped (8 active)	—	—	Mediastinal Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07283822Phase 2 · recruiting Amping up With PemJAK · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02996773Phase 1 · completed Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine · condition mapped ONTOLOGY_EXACT · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02153580Phase 1 · active not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia · condition mapped ALIAS · 18 trials mapped (8 active)	—	—	Gray-Zone Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains